Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials
Authors
Keywords
Bevacizumab, Progression-free survival, Overall survival, Safety, Ovarian cancer, Meta-analysis
Journal
Clinical & Translational Oncology
Volume 17, Issue 9, Pages 673-683
Publisher
Springer Nature
Online
2015-05-19
DOI
10.1007/s12094-015-1293-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
- (2015) Amit M Oza et al. LANCET ONCOLOGY
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials
- (2013) Qing Ye et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Phase III Trials of Standard Chemotherapy with or without Bevacizumab for Ovarian Cancer: A Meta-Analysis
- (2013) Mingyi Zhou et al. PLoS One
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Ten-Year Relative Survival for Epithelial Ovarian Cancer
- (2012) Lauren A. Baldwin et al. OBSTETRICS AND GYNECOLOGY
- Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer
- (2011) J. Alejandro Rauh-Hain et al. ANNALS OF SURGICAL ONCOLOGY
- Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer
- (2011) Jamie L. Lesnock et al. GYNECOLOGIC ONCOLOGY
- 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer
- (2011) Gavin C.E. Stuart et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Big Costs for Little Gain in Ovarian Cancer
- (2011) Martee L. Hensley JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies
- (2011) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
- At What Cost Does a Potential Survival Advantage of Bevacizumab Make Sense for the Primary Treatment of Ovarian Cancer? A Cost-Effectiveness Analysis
- (2011) David E. Cohn et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
- (2011) Beth Y. Karlan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients WithBRCA1orBRCA2Mutations and Recurrent Ovarian Cancer
- (2011) Stan B. Kaye et al. JOURNAL OF CLINICAL ONCOLOGY
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
- (2010) Michael Friedlander et al. GYNECOLOGIC ONCOLOGY
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
- (2010) Ignace Vergote et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial
- (2009) Maurie Markman et al. GYNECOLOGIC ONCOLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
- (2009) Ursula A. Matulonis et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
- (2009) Noriyuki Katsumata et al. LANCET
- Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
- (2009) Sanjaykumar Hapani et al. LANCET ONCOLOGY
- Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis
- (2008) Ifat Sher et al. INTERNATIONAL JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search